Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,828 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05432739Recruiting
Test a lung nodule blood/scan marker to find early cancer
This study looks at whether a new test can better identify early lung cancer in people who are being watched for an incidental lung nodule. It may help doctors decide which nodules need closer follow-up or treatment.
Goodmayes, EssexAges 18 years+ - NCT05913089RecruitingPhase 2
Testing a new lung cancer drug with chemotherapy or an anti-angiogenesis pill
This Phase 2 trial tests TQB2450 (a new cancer medicine) added to chemotherapy, or along with an oral medicine called anlotinib, for stage II–IIIB non-small cell lung cancer. It may help shrink tumors and improve outcomes in people who are getting curative surgery and have not had prior cancer drug treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT05934032Recruiting
Genomic medicine for non-surgical lung cancer
This trial is part of a lung cancer network that uses genetic (DNA) testing to better understand and treat non-surgical lung cancer. You might be eligible if you have certain stages of non-small cell lung cancer and can consent to participate.
CologneAges 18 years+ - NCT05838053Recruiting
Segmentectomy versus lobectomy for small lung cancer
This trial compares two types of lung surgery—removing a small lung segment versus removing an entire lung lobe—for small lung adenocarcinoma (≤ 2 cm). It may help you choose the safest approach that still controls the cancer.
Yangpu, Shanghai MunicipalityAges 20–79 - NCT06001151RecruitingPhase 2
Cadonilimab plus chemo for PD-L1 negative lung cancer
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy as a first treatment for people with advanced non-squamous non-small cell lung cancer that does not have the PD-L1 protein. The goal is to see if this combination works better than standard treatments.
Wuhan, HubeiAges 18–75 - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT04728724RecruitingPhase 2
Check immune treatment before surgery for stage III lung cancer
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
ShanghaiAges 18–75 - NCT06043973RecruitingPhase 3
Almonertinib plus anlotinib for first-line advanced lung cancer
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Jinan, ShandongAges 18–75 - NCT06041776RecruitingPhase 3
Befotertinib after surgery for early-stage lung cancer with EGFR mutation
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
BeijingAges 18 years+ - NCT05502913RecruitingPhase 2
Fecal transplant plus cancer immunotherapy for lung cancer
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
BeershebaAges 18 years+ - NCT06056115Recruiting
Tislelizumab for lung cancer with brain metastases
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Shijiazhuang, HebeiAges 18–75 - NCT05241028RecruitingPhase 2
Adjuvant ensartinib for ALK-positive lung cancer after surgery
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
Shijiazhuang, HebeiAges 18–75 - NCT06147570RecruitingPhase 2
Study of HS-10365 for RET fusion-positive lung cancer
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT02270476Recruiting
Study of how cystic fibrosis lung disease changes over time
This observational study follows children newly diagnosed with cystic fibrosis to understand how their lung disease develops. It may help doctors better predict disease course and choose the right timing for care.
Heidelberg, Baden-WurttembergAges Any age - NCT06052098Recruiting
Comparing two ablation methods for early-stage lung cancer
This study compares two ways to destroy early-stage lung cancer without surgery: one using a needle through the chest (CT-guided) and another using a thin tube through the mouth (bronchoscopy-guided). It might be an option if you have small, outer-edge lung cancer and cannot or prefer not to have surgery.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04992780RecruitingPhase 2
Hypo-fractionated radiation versus standard radiation for lung cancer
This study compares two different radiation schedules for stage III non-small cell lung cancer, both combined with chemotherapy and immunotherapy. It aims to see whether giving radiation in a different way can work as well (or better) and be safe while treating the cancer.
Kansas City, KansasAges 18 years+ - NCT06168032Recruiting
COVID-19 vaccine for lung cancer patients
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
BeijingAges 18 years+ - NCT07867730Recruiting
Breathing exercises help people on ventilators with stiff lungs
This study tests two breathing exercises, inspiratory muscle training and positive expiratory pressure, for people in the ICU on a breathing machine. It aims to see if these exercises can improve breathing and recovery for patients with restrictive lung disease.
IslamabadAges 18–60 - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06189820RecruitingPhase 2
FAP protein as a marker for fibrotic lung disease
This trial is looking at a protein called FAP in the blood of people with fibrotic lung diseases. It aims to understand how this protein might be used as a marker to help doctors better diagnose and track these conditions.
BrusselsAges 18 years+ - NCT04459065RecruitingPhase 1/Phase 2
Imaging medicine to help find lung cancer during surgery
This trial tests a special imaging drug (IRDye800CW-nimotuzumab) that may help surgeons better see lung cancer tissue during planned lung surgery. Phase 1/2 looks mainly at safety and how well the imaging works to guide the operation.
Saskatoon, SaskatchewanAges 18–80 - NCT07864207RecruitingPhase 1/Phase 2
Study of IDP-121 for small cell lung cancer that stopped responding to platinum
This trial tests a new drug, IDP-121, alone or with another chemo drug, for people with small cell lung cancer that came back after initial treatment. The goal is to see if it can shrink tumors and help people live longer.
BarcelonaAges 18 years+ - NCT07871656Recruiting
Detecting lung cancer in non-smokers through urine
This study uses a simple urine test to help detect lung cancer in people who have never smoked but have a lung spot (nodule) on their CT scan. It may lead to a new, non-invasive way to check for cancer without needing a biopsy.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06216782Recruiting
Neoadjuvant therapy for lung cancer: a real-world study
This study observes patients with lung cancer who receive neoadjuvant therapy (treatment before surgery) to understand how well it works in everyday medical practice.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,828 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.